Thursday, April 16, 2015 - 07:30

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic antibodies for the treatment of cancer and inflammatory diseases, today announced that it has entered into a collaboration agreement with Sanofi to apply Innate Pharma’s site-specific conjugation technology to the development of new Antibody Drug Conjugates (“ADC”).

Hervé Brailly, CEO and co-founder of Innate Pharma, said: “We are very pleased to collaborate with Sanofi, a global healthcare leader. By combining some of Sanofi R&D’s anti-tumor antibodies with our novel technology for conjugating cytotoxic compounds, this collaboration opens the gate to next-generation ADCs with a potentially improved therapeutic index for patients with cancer”.

Sanofi-Aventis Recherche & Développement, the French R&D affiliate of Sanofi, will evaluate site-specific payload conjugation to enhance ADC pharmacokinetics, efficacy and safety and has the option to enter into a licencing agreement with Innate Pharma on this technology. Other terms of the agreement are undisclosed.
 

AttachmentSize
PR in English34.41 KB
CP en français72.94 KB